Why Partner?
As evolving guidance and new innovations challenge the traditional regulatory pathways, many cell and gene therapy developers are prioritizing investments in support to clarify frameworks and aid in negotiations with regulatory bodies.
This October, prominent biopharma companies are seeking consultancy firms, CROs, CDMOs, regulatory software providers, and more to propel their pipelines to the next stage of development. Meet C-Level Executive, Vice Presidents, and Directors of regulatory affairs and regulatory CMC, spanning from pre-IND to post-BLA, who seek your expertise to support filings, negotiations, understanding of current and new guidance, and much more!
Position yourself as a pioneer of innovation and service provider of choice by showcasing your company at the inaugural Cell & Gene Therapy Regulatory Affairs Summit. This event promises a prime opportunity to network with regulatory leaders, decode the needs of biopharma, and foster new relationships to work toward your commercial goals in 2024.